Plain-English translation of NCT07264075 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether ivonescimab—a new immunotherapy medication—works better than pembrolizumab (a standard immunotherapy already used for this cancer) in treating head and neck cancer that has returned or spread to other parts of the body. You would receive either ivonescimab alone, or ivonescimab combined with another new medication called , and researchers will compare how well these treatments work compared to the standard treatment.
Head and neck cancer that comes back or spreads is very serious, and current treatments don't work well enough for all patients. Doctors hope this medication may help more patients live longer and control their cancer better.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new medication alone, the new medication plus a second medication, or the standard treatment. Every three weeks, you will receive your assigned treatment through an IV infusion—either a 1-hour infusion for the new single medication or the standard treatment, or a longer infusion if you receive the two-medication combination. You will continue treatment for up to 24 months or until your cancer stops responding, you experience intolerable side effects, or your doctor decides to stop treatment. Throughout the trial, you will have regular blood tests and imaging scans to monitor how your cancer is responding.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
France